Second-line therapy for small cell lung cancer: Exploring the potential role of circulating tumor cells

Translational Lung Cancer Research

Volumn 5, Issue 1, 2016, Pages 71-77

  Hamilton, Gerhard ^a   Rath, Barbara ^a   Holzer, Sophia ^b   Hochmair, Maximilian ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b OTTO WAGNER HOSPITAL   (Austria)

Author keywords

Chemosensitivity; Chemotherapy; Circulating tumor cells (CTCs); Epirubicin; Small cell lung cancer (SCLC); Topotecan

Indexed keywords

EID: 84960107428     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.12.12     Document Type: Article

References (29)

1. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer 2015;121:664-72.
2. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol 2014;41:133-42.
3. Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 2014;15:2385-96.
4. Asai N, Ohkuni Y, Kaneko N, et al. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 2014;6:69-82.
5. López-González A, Diz P, Gutierrez L, et al. The role of anthracyclines in small cell lung cancer. Ann Transl Med 2013;1:5.
6. Yu N, Zhou J, Cui F, et al. Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung 2015;193:157-71.
7. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in smallcell lung cancer. Nat Med 2014;20:897-903.
8. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32.
9. Huang CH, Wick JA, Sittampalam GS, et al. A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer. Front Oncol 2014;4:271.
10. Hamilton G, Rath B, Klameth L, et al. Small cell lung cancer: recruitment of macrophages by circulating tumor cells. OncoImmunology 2015. [Epub ahead of print].
11. Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung 2015;193:451-2.
12. Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/ YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res 2015;4:287-91.
13. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
14. Schmittel A. Second-line therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2011;11:631-7.
15. Schmittel A. Controversies in the treatment of advanced stages of small cell lung cancer. Front Radiat Ther Oncol 2010;42:193-7.
16. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993;11:1230-40.
17. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
18. Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 1994;26:428-38.
19. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
20. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
21. Khan MS, Kirkwood AA, Tsigani T, et al. Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clin Cancer Res 2016;22:79-85.
22. Zhang J, Wang HT, Li BG. Prognostic significance of circulating tumor cells in small--cell lung cancer patients: a meta-analysis. Asian Pac J Cancer Prev 2014;15:8429-33.
23. Luo YH, Tseng PC, Lee YC, et al. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. Cancer Biomark 2015. [Epub ahead of print].
24. Lee SJ, Lee J, Kim ST, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers 2015;30:e382-6.
25. Steinestel J, Luedeke M, Arndt A, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015. [Epub ahead of print].
26. Huang X, Gao P, Song Y, et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a metaanalysis. BMC Cancer 2014;14:976.
27. Mathew A, Brufsky AM, Davidson NE. Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res 2015;21:2421-3.
28. Khoo BL, Lee SC, Kumar P, et al. Short-term expansion of breast circulating cancer cells predicts response to anticancer therapy. Oncotarget 2015;6:15578-93.
29. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release 2015;201:78-89.